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Abstract
Thapa, Pariksha.

M.S., Department of Pharmacology and

Toxicology, Wright State University, 2019, Kinetics of Microvesicle
Particle Release in Keratinocytes

Microvesicle particles (MVPs) are subcellular particles that could be
involved in inter-cellular communication because they carry various
bioactive substances including cytokines. Previous studies from our lab
has shown that that the lipid mediator Platelet-activating Factor (1-alkyl2-acetyl-glycerophosphocholine; PAF) and ultraviolet B radiation (UVB)
enhances the release of MVP in various cell types like primary
keratinocytes, epithelial cell lines, and murine skin. We hypothesized that
there may be synergistic increases in MVP release after combination of
treatment of keratinocytes with UVB and PAF agonist (CPAF)/phorbol
ester (PMA). The combination treatment significantly increases MVP and
cytokine release at 4 to 8 hours time points. Imipramine, an acid
sphingomyelinase (aSMase) inhibitor blocks MVP and cytokine release
which indicates that MVP could be involved in cytokine release. The
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increased level of TNF-alpha in the supernatant was not present in the
MVP but surprisingly there was increased level of anti-inflammatory
cytokine, Interleukin 1- receptor antagonist (IL-1ra) inside MVP after UVB
treatment than in combination treatment, which could portray potential
imbalances between pro-inflammatory cytokines and down regulating
responses in exaggerated condition. These studies suggest that MVP
could play a role in how keratinocytes respond to UVB.

iv
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Chapter 1: Introduction

1.1 Statement of problem

Microvesicle particles (MVPs) are subcellular particles which have been
suggested to be important mediators in inter-cellular communication.
They are believed to carry various bioactive molecules like proteins,
nucleic acids, cytokines, RNAs and many other molecules from parent
cells to recipient cells through various mechanisms in both normal and

disease states. MVP are not only important biomarkers in various disease
states but also can be potentially used for diagnostic and therapeutical
purposes. Our group has previously found that various environmental
stressors increases the release of MVPs in skin keratinocytes.

We

hypothesize that combining these environmental stressors, will lead to
synergistic increase in MVP release along with cytokine TNF-alpha and
to determine the relation between cytokines release and MVPs are the
two main problems which this project is designed to address.

1

1.2. Significance

The significance of this study is that MVPs play important roles in
transporting various cytokines as they can travel to any parts of the body.
Thus, blocking these inflammatory cytokines could be new targets for
treating various diseases. Here our group has implicated Platelet
Activating Factor agonist and ultraviolet B Radiation in how these
stressors lead to release of MVPs and cytokines and are these cytokines
release and MVPs are interconnected to each other, as well as whether
combinations of these stressors could augment the release of MVPs and
cytokines. For an example, studies have shown that people with mild
hypersensitivity reaction when treated with ultraviolent radiation result in
Tumor necrolysis factor, leading to serious systemic effects 1. These
studies can provide important and clinically relevant insights in how the
regulation of the cytokines can be vital for the treatment of various
complications.

2

1.3. Statement of Purpose

The main purpose of this study is divided into two parts. First, we will
attempt to verify whether combination of two stressors PAF-R agonist and
UVB will increase the release of MVP along with cytokines. Does

treatment of human keratinocytes and epidermoid cell lines with CPAF
and UVB has synergistic effect in release of MVPs and cytokines? Does
the acid sphingomyelinase inhibitor imipramine block the release of MVPs
and

cytokines?

Second, Is

the

cytokines

and

MVPs

release

interconnected to each other? Do MVP carry these cytokines and to
potentially allow transfer to other parts of the body?

1.4. Hypothesis

Our hypothesis is that combination of PAF receptor agonist with
ultraviolet B radiation will lead to an increase in MVP release along with

3

cytokines in comparison with controls and individual treatments in human
epidermoid cell lines HaCaT and KBP.
Along with that, we expect that there will be a decrease in the release of
MVPs and cytokines when treated with acid sphingomyelinase inhibitor
imipramine. We expect that the exaggerated level of cytokines are
present in MVP and MVP act as a carrier of these cytokines.

1.5. Research objectives

➢ To determine if the combination of UVB and PAF receptor
agonist or phorbol ester increases the release of MVPs and
cytokines in a synergistic manner.
➢ To determine if the treatment with the aSMase inhibitor
imipramine blocks the release of MVPs and cytokines.
➢ To assess if the release of cytokines and MVPs are
interconnected with each other. Do MVPs carry cytokines
and transport these cytokines to different part of the body?

4

1.6. Assumption

We made the assumption that different skin keratinocytes and epithelial
cell lines respond in the same manner as the human system when treated
with different agents. The murine model used in the experiments respond

to all the treatments used in the experiment. The gender and age group
of mice will not affect the results with different treatment groups.

Chapter 2: Review of Literature

2.1. Introduction

Ultraviolet B Radiation (UVB), an environmental stressor is known to
cause both local and systemic effects in humans. Since UVB is known to
penetrate only the epidermal layer of the skin, the mechanism by which it
causes systemic effects are still unknown. We have previously published
that UVB induces Microvesicle Particles (MVPs) in dose-dependent
manner via Platelet Activating Factor Receptor (PAF-R)2. The increase in
the dose of UVB, there is an increase in the MVP release, but we believe
5

that when we combine two or more stressors like UVB and PAF agonist
there is synergistic increase in the MVP release even with a low dose of
UVB. The MVP do carry various proteins, cytokines and nucleic acid, and
we do believe that these MVP may carry inflammatory cytokines which
may cause systemic effect though UVB doesn’t penetrate the dermal

layer of the skin.

2.2. Microvesicle Particles

Microvesicle particles (MVPs; microparticles, microvesicles) are small
spherical shape vesicles, with a size of 100-1000 nm, which are secreted
by plasma membrane through outward budding basically by ecto-cytosis
processes3. Previously, it was considered as cell debris and was felt not
to serve any functions. MVP can be shed from almost all kinds of
eukaryotic cells in an energy dependent manner 3. Although there were

originally not many studies in this area, increasing interest in the
biogenesis and contents of MVP has changed the context about these
extracellular vesicles. MVP have been reported to contain various
bioactive substances like inflammatory cytokines, lipids, proteins and
nucleic acids 4.

6

They are also capable of transferring various biological information to the
target cells by direct fusion or internalization. However the mechanism of
how MVP transfers the biological content and their contribution in the
pathophysiology of different diseases are not completely known as yet5.
The exact mechanism of release of MVP in keratinocytes is not known
but there are several reports which has shown the mechanism of release
of MVP in other cell types. Among different pathways for release of MVP,
one of them is through the activation of ATP receptor P2X 7R. In the
microglial cells, the activation of inotropic ATP receptor P2X7R induces
MVP shedding. The activation of AT1P receptor enhances the release of
ATP from various degenerating cells or the lesion formed through the
propagation of ATP mediated Ca++ wave in the astrocyctes6. Another
known mechanism is through cleavage of Rho Kinase I (ROCK I) by
Capase 3, during apoptosis that leads to dysregulated activity of ROCK I
kinase and consequently leads to bleb formation7.
Most of the studies have reported that MVP regulation were associated
with ATP dependent P2X7R6,8. The first pathway is through P2X7R
mediated MVP release, the phosphatidylserine (PS) exposure at the
surface of the cell leads to loss of plasma membrane asymmetry and
there occurs the membrane blebbing. The second pathway is via
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activation of ATP receptor P2X7R, where acid sphingomyelinase
(aSMase) enzyme translocates from lysosomal region to the outer
plasma membrane9. Acid sphingomyelinase enzyme hydrolyze the
sphingomyelin lipid present in the cell membrane into ceramide and
phospholipid, causes membrane fluidity and induces membrane

destability, which facillitate membrane blebbing and MVP shedding10. It
is also noted that aSMase induced MVP release increased inflammatory
cytokines in MVP11. The generation of MVP from plasma membrane
represent the major process of release of cytokines in the glial cells and
the blockade of cytokine release from aSMase KO astrocytes is
confirmatory23. The acid sphingomyelinase enzyme inhibitors such as
imipramine block the release of MVP and inflammatory cytokines IL-1β in
the microglial cells6.

Figure 1. Mechanism involved in MVP shedding mediated by
P2X7R signalling pathway9.
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The stimulation of P2X7R with BzATP activates p38 MAPK cascade via
activation of src kinase-mediated phosphorylation. The stimulation of Pp38 triggers two different pathway along with plasma membrane pore
formation (a) and transfer of aSMase from lysosomal region to outer
plasma membrane (b) the aSMase enzyme alters the rigidity of plasma
membrane leading to MVP generation9.
Relatively little is known regarding MVP derived from keratinocytes. Yet,
it has been reported that MVP derived from other cell types contains
various cytokines like TNF-alpha from alveolar macrophages12 and
endothelial cells

13.

We hypothesized that MVP derived from

keratinocytes could contain

several cytokines

pathogenesis of various local and systemic effect.
9

and involved

in

Our lab has previously found that treating keratinocytes cell line with UVB
and PAF agonist (CPAF), HaCaT cells results in the release of MVP. And
importantly UVB irradiated in human epithelial KB cells transduced with
PAF receptor postive and negative cell lines, only PAF receptor positive
cell lines results in release of MVP. This proves that PAF signaling is

important in MVP release14. However the combination of UVB and PAFagonist will lead to exaggerated release of MVP in human keratinocytes
and mice model has not yet been studied. In this study, the combination
of UVB and CPAF in the production of MVP will be analyzed. From
different studies it is known that MVP carries various pro-inflammatory
cytokines like IL-1β, tumor necrosis factor (TNF-alpha) and Interleukin-6
(IL-6) increase the tumor growth and other complications 15. In this study
we will be addressing the correlation between MVP release and
cytokines. We hypothesize that MVP could be a potential carrier for
cytokines and could play a vital role in pathogenesis of several diseases.
Our laboratory has described a hypothetical model of UVB induced MVP
release. When a keratinocyte is irradiated with UVB, it stimulates PAF-R
and PAF agonist via reactive oxygen species. The created PAF agonists
acts on PAF-R and releases the aSMase enzyme from lysosomal
compartment to the plasma membrane. The aSMase enzyme breaks the
sphingomyelin lipids into ceramide and phosphocholine. The release of
10

ceramide in the plasma membrane tiggers MVP release. The aSMase
enzyme inhibitor, imipramine, inhibits the release of MVP.

MVP
release

aSMase

aSMase inhibitors
Figure 2. Hypothetical model of UVB induced MVP release in
human keratinocytes2,4.

2.3 Ultraviolet B Radiation

Ultraviolet Radiation (UV) is one of the main important environmental
factors that causes different complications like skin cancers, cutaneous
inflammation and both local and systemic immunosuppression16,17. The
UV radiation produced from the sun can be divided into three subtypes.

11

They are UVA (320-400nm), UVB (290-320nm) and UVC (100-290nm)18.
Only 5% of UVB and approximately 95% of UVA reaches the earth
surface. Though UVA is more prevalent than UVB, it is of lower energy.
UVA penetrates the deeper layer of skin and reaches the dermal layer18.
UVB which only reaches the epidermal layer of skin and thus cannot
penetrate the inner layer of skin (dermal layer) but exposure of UVB to
the skin has profound systemic effects19. When UVB is exposed to
epidermal layer of skin, the keratinocytes, releases many cytokines like
tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1, IL-8, IL-6, IL10, and, transforming growth factor-alpha (TGF-α), granulocyte colonystimulating factor (G-CSF), interferon gamma (INF-γ), macrophage-CSF,
platelet derived growth factor (PDGF), TGF-β, macrophage-CSF which
are involved in UVB induced inflammatory responses18,19. The enhanced
alarmin high mobility group box 1 (HMGB1) has profound effect in
generation of inflammatory responses in keratinocytes due to UVB20.
Various bioactive lipids, such as prostaglandin E2 and PAF are stimulated
by UVB radiation21. In human keratinocytes, UVB induces various protein
cytokines along with lipid mediator Platelet Activating Factor (1-O-alkyl-2
acetyl glycerophosphocholine, PAF)21. PAF is a very potent activator of
various cell types like monocytes, mast cells, leukocytes, acting via a G-
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protein coupled receptor. It plays a pivotal role in different signaling
pathways and is involved in pathological condition like oxidative stress
and bacterial infection22.
As mentioned earlier, UVB-induced MVP release is dependent on PAFR2,4. UVB and PAF activation leads to generation of several cytokines like
IL-1β, IL-6, IL-8, IL-10 and TNF-alpha18,19,26,27. In particular, combination
of both UVB and PAF-R agonist leads to synergistic increase in the
cytokine TNF-alpha release20, we are interested to learn if these
combination studies leads to exaggerated level of MVP and cytokines in
human keratinocytes. And the high level of TNF-alpha secreted by the
stimulated cells are carried by the MVP, a novel mechanism involved in
inter-cellular communication5.

2.4 Platelet Activating Factor Receptor (PAF-R)

Platelet Activating Factor (1-alkyl-2-acetyl-glycerophosphocholine; PAF)
is an important imflammatory phospholipid and is activated via G-protein
coupled receptor16. It is present in various innate immune system along
with keratinocytes23. PAF plays role in platelet aggregation, inflammation

13

and allergic reactions. Human keratinocytes (HaCaT) was found with
endogeneous PAF receptor24.
The activation of PAF receptor is triggered by various pro-oxidative
stressors like chemotherapeutic agents, cigarette smoke, aromatic
hydrocarbon and ultraviolet B Radiation. These stressors induces ROS
and acts on glycerophosphocholines (GPC) to produce PAF agonist,
oxidized GPC (ox-GPC),that activates the PAF- receptor25. The PAF is
also activated by carbamyl-platelet-activating factor (1-hexadecyl-2-Nmethylcarbamyl-glycero-3-phosphocholine; CPAF), a functional analog
of PAF, which is non metabolizable and can be used as stable PAF
agonist in in-vitro, ex vivo study and in-vivo studies21.
UVB irradiation in human skin can increase the formation of PAF/oxGPC21. UVB induces the release of reactive oxygen species (ROS), ROS
activates PAF-R. Activation of epidermal PAF-R result increased
synthesis of PAF, eicosanoids, COX-2 and cytokines like IL-6 and IL-8,
TNF-α21. Studies on HaCaT cells and KB cells transduced with PAF-R
showed that activation of PAF-R receptor results increased level of
cytokines (IL-6/IL-8) and cyclooxygenase (COX-2) which are known to
induce inflammatory responses26,27. This results in activation of several

14

signaling pathways, including protein tyrosine kinases, phospholipases
and phosphatidylinositol-3-kinase26,27.
From previous studies it is known that PAF is synthesized by UVB
radiation. Either, PAF-R or UVB produces tumor necrosis factor (TNF-α),
a mediator of cutaneous inflammation13,14,21. Previous studies has shown
that activation of PAF-R along with combination of UVB results in
synergistic TNF-alpha production in human PAF-R-expressing KB cells
and as well as murine skin20. This finding could have possible clinical
importance in treatment of photosensitive disorders20.
Though UVB irradiation is only absorbed in the epidermal layer, it can

cause systemic effects. Thus, mediators like extracellular particles which
can circulate in the microenvironment could potentially transfer cytokines
and PAF agonists from skin epidermal layer to the whole body has known
to have important role28.
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2.5 Cytokines

Cytokines are glycoproteins produced by many immune cells like
neutrophils, monocytes, macrophages, T-cells and B-cells to regulate
immune responses and involved in regulation of immune responses16.
They are involved in various physiological functions and inflammatory
responses29. They are sub-divided into various classes like Interleukins
(ILs) of which 35 has been described30, tumor necrosis factors (TNFs),
interferons (IFNs), transforming

growth factors (TGFs), colony-

stimulating factors (CSFs), and various chemokines16,28. It has been
found that in atherosclerosis, pro-inflammatory cytokines and Th-1
related cytokines enhance the progression and development of several
diseases while on the other side anti-inflammatory and regulatory T cell
related cytokines induces anti-atherogenic activities29. In this project we
emphasized on Tumor necrosis factors (TNF-alpha) and 27 other
cytokines level were analyzed in the MVP. They are: Interleukins ( IL-1β,
IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17), FGF
basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1(MCAF), MIP-1α,
PDGF-BB, MIP-1β, RANTES, TNF-alpha and VEGF.

16

2.5.1 Tumor Necrosis Factor (TNF-alpha)

TNF-alpha is a pro-inflammatory cytokines which is involved in regulating
inflammatory responses31. It is involved in cell proliferation, differentiation
and cell death32. It is released by monocytes, macrophages, T-cells, B
cells and fibroblast31,33. It is potent stimulator of autocrine and paracrine
which enhances release of inflammatory cytokines like IL-1, IL-6, IL-8 an
granulocyte-monocyte colony stimulating factor31,33. TNF-alpha is known
to

induce

various

inflammatory

responses

like

atherosclerosis,

rheumatoid arthritis, cancers and toxic epidermal necrolysis1. TNF-alpha
exerts its biological functions through activation of different pathways like
nuclear factor KB (NF-KB) and c-Jun N-terminal kinase (JNK)32. These
signaling pathways are involved in cancer biology with main emphasis on
cancer biology and carcinogenesis32.

Previous studies have found that higher level of TNF-alpha was found in
the skin lesions of psoriatic patients compared to normal skin34. Reactive
oxygen species from various environmental stressors like UVB, dietary
toxicity and drug metabolites enhances the level of TNF-alpha in primary
keratinocytes34. The induction of TNF-alpha from keratinocytes is mainly
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associated with UVA or UVB irradiation leading to photodamage and
photoaging35. The combination of UVB with other cytokines like IL-1α
upregulates the expression of mRNA level of TNF-alpha in human
keratinocytes35.
Primary keratinocytes are known to generate and release a variety of
soluble mediators such as IL-1β, IL-6, IL-8, TNF-alpha and other
transforming growth factors. These cytokines mediate local inflammatory
responses in the epidermis and also they can enter the circulation and
cause systemic effects36.
In our studies, the primary focus is to study the role of MVP in the level of

TNF-alpha generated via ROS induced by UVB in human keratinocytes.
The high level of TNF-alpha in the supernatant from the stimulated cells,
not only cause local effect in epidermal layer but also can induce systemic
effect via circulation in the body system.

2.5.2 Interleukin 1 Beta

Interleukin 1 Beta (IL-1-beta) is a pro-inflammatory cytokine derived from
monocytes, macrophages, dendritic cells as well as B-lymphocytes and
NK cells36. It is one of the most studies cytokines in IL-1 family37. It is
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important cytokine involved for host defense in injury and infection37. IL1β inhibitors are used in the treatment of autoinflammatory skin
diseases38.

2.5.3 IL-1 Receptor antagonist

It is also known as Anakinra, which is used to treat autoimmune disorders
and different types of cancer. It belongs to IL-1 family but do not cause
inflammatory responses. IL-1ra completely antagonizes the effect of IL1 beta and IL-1 alpha. It has naturally occurring anti-inflammatory effects
which are unique. Skin keratinocytes, epithelial cells, stromal cells,

hepatocytes and adipocytes all have been reported to secrete IL-1ra39.

2.5.4 Interleukin 2

Interleukin 2 (IL-2) is a cytokine with a very complex signaling pathway,
secreted from keratinocytes, macrophages, THCs, CTLs. It is mainly
involved in T cell signaling but also has been implicated in processes
such as wound healing40. It is involved in T-cell induction and proliferation.
Absence of IL-2 in murine model was found to be prone to autoimmune
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disorders40. It is also involved in cellular communication via complex
receptors. IL-2 is used clinically as immunotherapy in patients with
infectious diseases and disseminated cancer41.

2.5.5 Interleukin 4

Interleukin 4 (IL-4) is anti-inflammatory cytokine which helps in down
regulation of autoimmunity by suppressing of TH1 cells42. IL-4 is mainly
released by mast cells, eosinophils, basophils and TH2 cells 43. This is
involved in growth and differentiation of CD4+T lymphocytes into TH2
cells44.

2.5.6 Interleukin 5

Interleukin 5 (IL-5) is a pro-inflammatory cytokine, expressed in NK, NKT
cells and eosinophils, and other non-hematopoietic cells45. The signaling
pathway involved in IL-5 is through activation of JAK/STAT pathway46. IL-

5 effects the eosinophils migration and differentiation leading to allergic
inflammation47.
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2.5.7 Interleukin 6

Interleukin 6 (IL-6) is a pleiotropic cytokine which has very important role
in acute phase reaction48. It plays important role in chronic inflammation,
fibrogenesis, endothelial dysfunction, and autoimmunity48. Its expression
is high in autoimmune diseases and inflammatory conditions 49. The
various stimuli such as Toll-like receptor ligands, IL-1, IL-7, TNF-alpha,
PAF and physical exercise are involved in the release of IL-616.

2.5.8 Interleukin 7

Interleukin 7 (IL-7) is a potent cytokine which stimulates T-cells in normal
as well as disease state in T-cell expansion and differentiation. It is
involved in various autoimmune diseases like inflammatory bowel
diseases, rheumatoid arthritis and multiple sclerosis50. IL-7 can cause

joint destruction via activation of immune system51.
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2.5.9 Interleukin 8

Interleukin 8 (IL-8) belongs to CXCL family, which is activated by various
stimuli like TNF-alpha, IL-1β, hypoxia, androgens and estrogens52. It is
particularly secreted by monocytes, neutrophils, macrophages and

involved in acute inflammatory responses52. The IL-8 and its receptor is
involved in gliomagenesis and tumoral angiogenesis53.

2.5.10 Interleukin 9

Interleukin 9 (IL-9) is pro-inflammatory cytokines involved in various
immune pathological conditions and inflammatory diseases ranging from
asthma to parasitic infections54. IL-9 has effect on both mast cells and Tcell growth and proliferation. It can promote Th17 cells and its
development55.
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2.5.11 Interleukin 10

Interleukin 10 (IL-10) is an anti-inflammatory cytokine which decreases
the activation of T-cells, monocytes and macrophages56. The primary
function of IL-10 is to inhibit the inflammatory responses56. It is also
known that overexpression of IL-10 in some tumors and lymphomas can
promote further tumor development57.

2.5.12 Interleukin 12

Interleukin 12 (IL-12) is a pro-inflammatory cytokine which secreted by
activated antigen presenting cells such as monophages, dendritic cells
and macrophages58. It has been found to upregulate TH2-type cytokines.
Polymorphisms of IL-12 is involved in various risk for cancer
progession59.
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2.5.13 Interleukin 13

Interleukin 13 (IL-13) is a pro-inflammatory cytokine which is released by
T-cells and dendritic cells. IL-13 and IL-4 shares the same IL-4 alpha
complex receptor and share common biological functions involving signal
transduction60. It activates mast cell, eosinophil and neutrophil function
as well as play vital role in allergic airway diseases61. Studies has shown
IL-13 reduces cardiac injury and heart dysfunction through M2
polarization62.

2.5.14 Interleukin 15

Interleukin 15 (IL-15) is a pro-inflammatory cytokine which is very unique.
During inflammation or stress it is neither secreted nor upregulated on
cell surface. Its expression is dependent on private IL-15R alpha chain63.
Upregulation of IL-15 has been found in various autoimmune diseases63.
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2.5.15 Interleukin 17

Interleukin 17 (IL-17) is recently discovered cytokine that is produced
exclusively by T-cells and variety of innate cells like macrophages, natural
killer cells, dendritic cells. It promotes inflammatory responses in

autoimmune diseases and other various inflammatory diseases64.
Targeting IL-17 has been important therapeutic strategy in the treatment
of plaque psoriasis65.

2.5.16 Eotaxin

Eotaxin is a chemokine which is produced by different cells such as
macrophages, eosinophils, lymphocytes, endothelial cells, respiratory
cells, smooth muscle cells, fibroblast and keratinocytes65. It has been
reported that eotaxin promotes the vascular smooth muscle cells
activation and play important role in the cardiovascular disease,
especially in elderly patients66.

2.5.17 Granulocyte colony stimulating factors

Granulocyte colony stimulating factor (GMCSF) is a glycoprotein that
induces survival, proliferation, differentiation and function of neutrophil
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granulocytes and their precursors67.It is the major cytokine that regulates
the function of neutrophilic granulocytes. Recombinant GCSF has
become common in treatment of neutropenia68. It is known that the mice
model lacking GCSF has chronic neutropenia and granulocytes66.

2.5.18 Interferon gamma

Interferon gamma (IFN-gamma) is an important cytokine that induces and
modulates immune responses. It is produced by T-cells and natural killer
cells (NK)69. It functions through JAK-STAT signalling pathway70. It has
different

functions

such

as

activating

innate

immune

system,

macrophages, mediating balance between TH1 and TH2 cells, controlling
cellular proliferation and apoptosis.

2.5.19 Macrophage inflammatory protein alpha

Macrophage inflammatory protein alpha (MIP-1α) is a pro-inflammatory
chemokine secreted by different cells such as dendritic cells,
macrophages and lymphocytes72. It plays important role in inflammation
associated to Rheumatoid arthritics72. MIP-1α is important in the
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regulation of T-lymphocytes and monocytes. It plays vital role in
stimulation of other cytokines especially TNF-alpha, IL-1 and IL-6 and the
degranulation of mast cells, and the initiation of macrophage-derived
inflammatory responses73.

2.5.20 Platelet derived Growth factor- BB

Platelet derived Growth factor (PDGF) acts via two receptors PDGFRalpha and PDGFR- beta74. PDGF are important in angiogenesis or
endothelial progenitor cells and mesenchymal stem cells. Increased level
of PDGF-BB is found in several diseases such as pulmonary

hypertension, retinal vascular disease and dermal fibrosis74.

2.5.21 Regulated on activation, Normal T-cell Expressed
and secreted (RANTES)
RANTES is also called as CCL5, are important chemokine that play role
in stimulation of natural killer cells, T-cells, monocytes, eiosinophils and

dendritic C. It is secreted from cells like epithelial cells and platelets75’76.
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2.5.22 Monocyte chemoattractant Protein 1

MCP-1 is a important chemokine which is induced by many cells either
by oxidative stress, cytokines and growth factors77. It is mainly secreted
by endothelial cells, epithelial, smooth muscle, mesangial cells,

monocytic and microglial cells77. MCP-1 are found over expressed in skin
lesions, tissue fibrosis and systemic sclerosis78.

2.5.23 Vascular Endothelial Growth factors

VEGF activates tyrosine kinase enzyme by binding to the tyrosine kinase

receptor thus stimulating intracellular pathways79.

It is released by

vascular endothelial cells and to some extent to non-endothelial cells79. It
is involved in the pathogenesis of angiogenesis, tumors, ischemia and
inflammation79.

2.5.24 Fibroblast growth factors
FGF has significant effects on the growth and regeneration of tissues80.
It is expressed in cells and tissues and found in both vertebrate and
invertebrate80. It comprises of 22 members and early it was thought to
promote fibroblast proliferation. Its main funtion is to enhance
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mitogenesis, angiogenesis, wound healing, cellular migration and
differentiation80.

2.5.25 Granulocyte Macrophage Colony-Stimulating
Factor

GM-CSF is an important cytokine involved in regulation of macrophage
numbers and functions81. It is generated by number of cells like
fibroblasts, osteoblast, smooth muscle and macrophages. Higher levels
of GM-CSF are found in various complications such as inflammation,
cancer and autoimmune diseases81. It activates the monocytes and
macrophages and also helps in differentiation to other state and involved
in immune responses81.
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2.5.26 Interferon-γ-Inducible-Protein-10 Interferon

It is also known as CXCL-10 which is released from different cell lines
such as keratinocytes, leukocytes, eosinophils, monocytes, netrophils
epithelial cells. It plays major role in cell growth, apoptosis and angiostatic

effects. It is also important mediator in migration of T-cells, NK cells and
monocytes82.

2.5.27 Macrophage Inflammatory Protein (MIP)

MIP is a inflammatory protein that is sub-divided into two different

chemokines, MIP alpha protein (MIP-1α) and MIP beta protein (MIP-1β).
MIP-alpha is secreted form different cells like moncytes, T lymphocytes,
B lymphocytes, dendritic cells, basophils, fibroblast83. Similarly MIP-beta
is also secreted from Monocytes, NK cells, dendritic cells, microglia and
neutrophils83. It plays major role in migration and activation of monocytes,
neutophils, eosinophils and basophils83.

2.6 Microvesicle particles (MVP) and Cytokines

The release of MVP is a important means of intercellular communication
which is shared by many cell types, mainly they are involved in transfer
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of cell contents. The released MVP can enter the body fluids and
potentially travel to other tissues84. MVP are capable of transfering cargos
loaded from the parent cells to other neigbouring cells or distant tissue
and play role in inflammatory diseases including cancers, angiogenesis
and artherosclerosis27,5.The agents carried by MVP depends on the

parent cell type. In microglial cells, astrocyte-derived ATP induces the
formation of MVP and cytokine (interlukin-1β), IL-1β found to be present
in MVP which subsequently efflux in the extracellular environment 86. IL1β, key initiator of acute inflammatory responses, enhanced by ATP
stimulation was inhibited by P2X7R antagonist20,30. IL-1β release in the
microvesicle by ATP stimulation has been studied in time dependent
manner. The release of IL-1β was found as early after 2 minutes of
stimulation and the concentration of IL-1β changes with the time37. In one
of the study it is found that microvesicle shedding is due to activation of
acid sphingomyelinase enzyme and also IL-1β secretion is dependent on
aSMase.

MVP shedding and IL-1β release is blocked by aSMase

inhibitor, imipramine9. The aMAase KO astrocytes have been reported to
have decreased MVP shedding and IL-1β release, which can be restored
by addition of P2X7R agonist23.
Based upon these disparate literature reports and our own laboratory’s
findings, we hypothesize that the concentrations of cytokines or proteins
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in the MVP and even shedding of MVP may change in time dependent
manner. The study of kinetics of MVP shedding and generation of
several other cytokines along with IL-1β could be important study to learn
more about the role of MVP in different diseases. In this study, we on
cytokines like tumor necrosis factor (TNF-alpha). As mentioned earlier,

acid sphingomyelinase inhibitor can block MVP shedding and IL-1β in
microglial cells and astrocytes31,23. There are very few studies going on
keratinocyte derived MVP, but it could be very possible that several
keratinocytes derived MVP could contain different kinds of cytokines. In
this study, we have hypothesized that keratinocyte derived MVP could
contain possible cytokines (TNF-alpha) and they could transfer these
inflammatory cytokines to different parts of the body leading serious
complications like cutaneous inflammation, psoriasis and toxic epidermal
necrolysis1.
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2.7 Toxic Epidermal Necrolysis

The wide spread use of drugs has increased with advancement in
research and development in the field of medicine. Along with benefits
there are considerable morbidities associated with the adverse reactions
associated to drugs. Toxic Epidermal Necrolysis (TEN) is mainly drug
induced reaction. It is very rare but severe life-threatening disorder87. It is
the most severe amongst the epidermolytic adverse cutaneous drug

reactions. TEN is characterized by keratinocyte cell death that separates
skin layer at dermal-epidermal junction followed by bullous de-attachment
and skin sloughing86,87,89. The cell death and mucous de-attachement
leads to other symptoms which includes anxiety, high fever, mucosilitis,
severe pain, asthenia, genitourinary, ocular damage. The underlying
mechanism of TEN is still unkown, yet it has been reported that the blister
formed at the conjuction of dead epidermis and dermis has high levels of
cytokines like TNF-alpha, IL-12, IL-1889. Other studies have shown that
high level of TNF-alpha and IFN- activates the Inducible Nitric Oxide
Synthase leading to severe conditions90.
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Though multiple cases of TEN have been reported, the exact mechanism
for this life-threatening condition is unknown. In 2010, there was a case
of TEN in a 22 year old young girl who was absolutely healthy other than
mild drug hypersentivity reactions to non-steroidal anti-inflammatory
drugs. She developed a mild allergic reaction with red macules and

papules on her back, chest and fore-arm after the ingestion of 200mg
Ibuprufen. Two days after the rashes and allergic reaction in order to self
-treat, she went to bed tanning therapy with UV (UVA + UVB) light.
Unfortunately, after 4 hours of UV light exposure she developed itchiness
and rashes in the skin exposed to UVB. The next morning skin blister
formation started with irritation in throat, redness, swolling and vaginal
abnormalities. Eventually she was admitted to the hospital, the skin
biopsies and blister from affected area was tested. The presence of high
level of TNF-alpha in the blister and skin biopsies compared to control
was very suprising91. The Ultraviolet light causes keratinocyte damage
leading to cell death and

generation to cytotoxic cytokines in the

epidermis. It was quite suprising how the TNF-alpha present in the skin
blister and biopsy reaches the system of the body. At presently, our lab
is focused in the study of MVP particles, and we have hypothesized that
these extracellular vesicles could be loaded with exaggerated level of
cytokines generated due to combination of UV light and drug
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hypersensitivity reaction and circulate throughout the body causing
systemic effect described in this incident.

Figure 3. Clinical photographs of skin biopsy and blister
formation showing toxic epidermal necrolysis and tumor
necrosis factor (TNF-alpha)91.

2.8 Imipramine

Imipramine is tricyclic antidepressant drug clinically used in the treatment
of neuropathic pain and major depression 92. Four decades ago,
imipramine was discovered as a potent drug that has ability to inhibit the
acid sphingomyelinase enzyme92. Acid spinghomyelinase enzyme is a
known lysosomal enzyme present in lysosomal compartment, which
translocates from lysosomal region to plasma membrane. aSMase
enzyme hydrolyses sphingomyelin lipid into ceramide in the plasma
membrane93. The production of ceramide in the outer plasma membrane
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activates the intracellular molecules which are involved in transmission of
various signals92. It is also known that deficiency of aSMase enzyme
leads to Type A and Type B II Niemann-Pick diseases (NPD). It is also
found that stimulation of aSMase enzyme via PAF-R activation increases
vascular permeability in acute lung injury94. The aSMase KO mouse has

been created, which mimics many aspects of the human Niemann-Pick
disease. aSMase KO mouse have been reported to be resistant to
radiation, stress induced apoptosis like FAS or CD95, ischemia,
chemotherapy and tumor necrosis factor alpha95,96,97.
Previous studies have shown that UVC light induces translocation of
aSMase from lyosomal region to plasma membrane. The stimulation of
UVC light induces ROS generation which enhances aSMase enzyme
translocation and PDTC, anti-oxidant inhibited the translocation of
aSMase enzyme98. This supports the hypothesis that UVC light via ROS
generation stimulates translocation of the aSMase enzyme, resulting in
the upregulation of ceramide levels in the plasma membrane. It has been
found that high level of ceramide mediates UV signals resulting in
mitochondrial DNA damage94.
The activation of acid sphingomyelinase enzyme and production of
ceramide induces extra cellular vesicles particularly MVP in microglial
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cells. Acid sphingomyelinase pathway through activation of P2X7R is a
major mechanism involved in MVP generation9. Along with MVP,
cytokines like TNF-alpha and IL-1β are secreted via activation of P2X7R
receptor through the acid sphingomyelinase pathway11,96. TNF-alpha and
IL-1β are two major cytokines that cause apoptosis and inflammation in

neuronal cells. TNF-alpha and IL-1β induced apoptosis and inflammation
are correlated with increased levels of ceramides. The suppression of the
aSMase pathway in glial cells decreased ischemic damage in
neurons95,86. It is believed that secretion of cytokines in the MVP is a
major mechanism of release of cytokines from microglial cells.
Imipramine, acid sphingomyelinase inhibitor, blocks MVP and IL-1β from
microglial cells and aSMase KO astrocytes11,85.
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Chapter 3: Materials and Methods
1.1 Introduction-

In this chapter we will discuss the model systems, materials, procedures
and analysis performed to acquire the relevant data to answer the
experimental questions of this study. The model systems used in this
study are mainly in-vitro cell lines and an in-vivo murine model.

1.2 Cell culture-

There were three cell lines used in the experiments, spindle- shaped
HaCaT cell lines, derived from spontaneously immortalized human
keratinocytes.

KB

cells were

isolated from

a patient

with

a

nasopharyngeal carcinoma. The cells were later transduced with
MSCV2.1 retrovirus containing PAF-R (KBP) and KBM cells with control
MSCV2.1 retrovirus without PAF-R99.

1.3 Cell growth media and storage condition

Complete media containing Dulbecco’s modified Eagle’s medium (DMEM
Hyclone, Logan, UT) added with 10% fetal bovine serum (Hyclone,
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Logan, UT), 100 U penicillin/0.1 mg/ml streptomycin (5ml),and 2mM
glutamine (5 ml) was used to grow the three cell lines, HaCaT, KBP and
KBM. All the cells were kept at 37ºC and 5% C02 in humidified incubator.

3.4. Cell passage
Growth media were removed from the culture plates and culture plates
were washed 3 times with 10 ml of PBS 1X. 0.25% of Trypsin-EDTA 1X
(for HaCaT) and 0.05% of Trypsin-EDTA 1X (KBP/KBM) was added to
each plate and incubated for 10 minutes. Then, when cells start to deattach from the plate add 8ml of media to each plate to bring the volume
to 10ml and then cells were triturated. For normal cell passage, 6 drops

of the cells suspended in media was added to new plate with fresh media
10 ml. For HaCaT cells 2.5 ml of cells were added to 10 ml of fresh media
in 10 cm2 plates.
The cells which needed to be treated were counted before adding to the
new plates and ensure that equal number of cells are added to each plate.
The number of days required for the cells to get confluent had crucial role
to get the consistent results. For consistent results, every time cells were
counted and grown for an equal number of days.
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1.4 Changing media

To change the media, the old media was removed from the culture plate,
and the plate was washed thrice with 10ml PBS 1X. Then 10 ml of fresh
media was added. The media is changed roughly every 2-3 days between
passaging.

1.5 Cell count

To count the cells, first cells were washed thrice with 10 ml PBS 1X. Then
procedure of addition of trypsin was followed and then 200µl of cells
suspended in fresh media were added to 800µl of PBS 1X in 1.5 ml of
microcentrifuge tubes and total number of cells were counted with
Millipore Scepter handheld automated cell counter.

40

1.6 Bringing up cells from liquid Nitrogen

The vials after taking out from Liquid Nitrogen, were thawed in hand and
cells were immediately added to new culture plate containing 10 ml of
fresh media. The next morning cell were fed and then passage into new

plates after the cells are confluent.

1.7 Treatments

3ml of Hank’s Balanced Salt Solution and 10mg/ml Bovine serum albumin
(HBSS+BSA) with desired concentration of treatments reagents were
added to each plate. Sham culture plates received no treatment and were
incubated for desired length of time. Vehicle treated cells received 0.1%
of Ethanol and HBSS+BSA. CPAF treated cells received 3µl of 100µM
CPAF added to 3 ml of HBSS+BSA to obtain final concentration of
100nM. PMA treated cells received 3µl of 500µM PMA added to 3 ml of
HBSS+BSA calculated to final concentration of 500nM. UVB treated cells
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received 600 J/m2 for 2 minutes with lids off. For the combination
treatment, CPAF+UVB, 3 µl of 100µM CPAF and 3 ml of HBSS+BSA was
added and incubated for half an hour in the incubator. After half an hour
the culture plates were irradiated with 600 J/m₂ of UVB. Then the plates
were incubated for desired duration of time. For, PMA+UVB, 3µl of 500µM

of PMA and 3ml of HBSS+BSA were added together and incubated for
30 minutes. Then 600J/m2 of UVB was irradiated for 2 minutes and
incubated for required time. For time response study, the samples were
collected in between 0-4 hours, 4-8 hours and 8-24hours time period.
After the collection of samples at each time point, the fresh HBSS+BSA
was added to the plates and incubated for required time period.
For the dose response study, several doses of CPAF (1nM, 10nM, 50nM,
100nM, 200nM & 250nM) and UVB (200 J/m2, 400 J/m2 , 600 J/m2, 800
J/m2, 1000 J/m2) were added according to the calculated volume along
with 3 ml of HBSS+BSA in each plate and the supernatant was collected
after 6 hour time point.

1.8 Inhibitors

After the plates were washed thrice with Hanks Balanced Salt Solution
(HBSS). Imipramine, an aSMase inhibitor used in the experiments was
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added to the plate and incubated for 1 hour before the treatment. 3 µl of
50 mM Imipramine with 3 ml of HBSS +BSA was added to each plate to
make final concentration of 50µM and incubated for 1 hour before the
treatment. But for UVB, the inhibitors were added after the UVB treatment
because imipramine has sunscreen effect which blocks the UVB.

1.9 MVP isolation

After the determined incubation time, 2ml of supernatant from the treated
culture plates were transferred to 2 ml centrifuge tubes and centrifuged
immediately in microcentrifuge tubes at 2000 x g for 20 minutes at 4ºC.
Then the supernatant was transferred to new tube and centrifuged at
20,000 x g for 70 minutes. After the centrifugation that supernatant was
discarded, and the pellet was re-suspended in 100µl of 1x PBS. The

samples were analyzed with Nano Sight NS300. Before analyzing the
sample, the particles should be diluted according to the threshold of the
Nano Sight NS300.
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1.10

Analysis

The reading obtained from the Nano Sight NS300 was multiplied by the
dilution rate and then divided by the cell count. The total MVP count
normalized with cell number were multiplied by 100,000 cells. The errors

were calculated for each treatment groups and graphed on GraphPad
Prism 8 and analyzed with one-way and two-way ANOVA to show
significance with a 95% confidence interval.

1.11

ELISA (Enzyme Linked Immunosorbent Assay)

Human high sensitivity TNF-alpha kit from Thermo Fisher Scientific was
used to quantify the concentration of TNF-alpha in the supernatant
isolated after the treatment with 100nM CPAF, 500nM PMA, 600 J/m2
UVB and combination of CPAF/PMA with UVB. The supernatant for
ELISA was collected from the same culture plate used to collect
supernatant for isolation of MVP. The procedure was completed following
the protocol from the kit. Then the plate was read in micro-plate reader.
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Standard curve with known concentration of TNF-alpha was used as
reference for the calculation of actual concentration.

1.12

Cytokine Expression Assay

HaCaT and KBP cells were treated with 100nM CPAF, 500nM PMA, 600

J/m2 UVB and combination of CPAF/PMA with UVB, MVP and
supernatant were extracted in between 4 to 8hours time frame. The total
protein content was analyzed in both MVP and supernatant with protein
assay. MVP concentration were measured with NanoSight Instrument.
Then samples were given to Dr. David Cool to conduct a Bio-plex ProTM
Human Cytokine 27-plex Assay to analyze MVP contents for human
cytokine expression. 27 cytokines were analyzed: FGF basic, Eotaxin, GCSF, INF-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12 (P70), IL-13, IL-15, IL-17, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β,
PDGF-BB, RANTES, TNF-alpha, and VEGF.
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1.13

Mice

C57BL/6EGFP wild type mice were obtained from Indiana UniversityPurdue University Indianapolis (IUPUI). Mice were housed together,
provided with water and food ad libitum in a 12 hours light and dark cycle

room. The protocol for the experimental use of animals was approved by
Wright State University, School of Medicine’s Laboratory Animal Care
and Use Committee (LACUC).

1.14

Treatment

Mice were injected with ketamine/xylazine, shaved and treated with 100
µl of 100 nM CPAF and the skin was irradiated with 1000 J/m2 of UVB.
For the combination treatment, shaved back was treated with 100nM
CPAF for an hour and then irradiated with 1000 J/m2 of UVB. The mice
were then placed in the cage for 4hours incubation time period.

1.15

MVP extraction from Punch Biopsies

After 4hours of incubation time period 5 mm punch biopsies were taken
from the treated skin on the back and each skin biopsies were individually
weighed. The skin biopsies were placed in 2ml microcentrifuge tubes and
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500 µl of 5 mg/ml collagenase dispase made in1:1 H2O and TrypsinEDTA (0.5%) no phenol red was added to each tube. The tissue was
finely chopped in the microcentrifuge tube and digested overnight in the
shaker at 37ºC. After the overnight digestion, 500 µl of filtered PBS was
added and then centrifuged at 2000 x g for 20 minutes. Then supernatant

was transfered to clean microcentrifuge tubes and centrifuged at 20,000
x g for 10 minutes. Then the supernatant was moved to a clean
microcentrifuge tube and centrifuged at 20,000 x g for 70 minutes.
Supernatant was discarded and the pellet was re-suspended in 100µl
filtered PBS (1X). Samples were stored at -80ºC until analysis.

1.16

Blood sample collection

At the same time blood was collected from the mice, euthanized in CO₂
tank and cervically dislocated. The blood was drawn from the heart of a
mice with 1ml of 30g BD syringe and collected in the microcentrifuge
tubes. Blood plasma was isolated by centrifugation at 2000 x g for 20 min
and the blood plasma (upper clear layer) was isolated pipetted in new
tube carefully. The MVP was isolated after centrifugation at 2000 x g for
20 minutes and 20,000 x g for 70 minutes.
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3.18 Analysis
Mean and significance were determined, and graphs were made using
GraphPad Prism 8. Data is expressed as mean± standard error. Groups
were compared using one-way ANOVA. Differences in sample were
considered significant if the P values were less than 0.05. Notation within

the figure include P<0.05 (*), P<0.01(**), and P<0.001(***).
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Chapter 4: Results
4.1 In-vitro studies

The first part of our studies was to determine dose response effect of
various stimuli. It was important to study the dose response curve to
determine the potential dose that could augment MVP release without
inducing maximal and/or toxic effects. Previous studies from our group
have shown that higher fluences of UVB (above 1000 J/m2) are needed
to induce increased levels of MVP release 2. UVB induced MVP release
is PAF- dependent2.

We already know UVB and PAF-R activation

induces MVP release in dose dependent manner. But we are focused to
study what could be the outcome when we combine these stimuli. The invitro study was done in human epidermal cell lines, HaCaT and PAF-R
positive cell line KBP cells.

4.2 HaCaT cells

4.2.1 Dose response study of CPAF and UVB in HaCaT
cells
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To determine the appropriate dose for the combination study, a dose
response curve was highly important. To determine the dose response
effect of CPAF and UVB on HaCaT cells, various doses of CPAF (1nM,
10nM, 50nM, 100nM, 200nM, 250nM) and UVB (200 J/m2, 400 J/m2 ,600
J/m2, 800 J/m2, 1000 J/m2) were used to treat keratinocyte derived

HaCaT cells and incubated at 37ºC for 6 hours. As shown in Fgure 4a,
HaCaT cells responded to 50nM, 100nM CPAF with increased level of
MVP compared with control. There was significant increase in MVP
release with 200nM of CPAF compared to control. Increased
concentrations of CPAF induces high level of MVP until 200nM and then
there was decrease in the level of MVP. These studies suggest that high
concentration of CPAF may cause cell death leading to decrease in
release of MVP. In Figure 4b, we investigated the appropriate dose of
UVB that could be used to obtain a synergistic release of MVP without
overwhelming the cells. HaCaT cells treated with 600 J/m2 UVB has no
significant increase in MVP compared to control. Higher doses of UVB

(800 J/m2 and 1000 J/m2) has significant increase in MVP release
compared to control.
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Figure 4. Dose response study of MVP release from CPAF and
UVB in HaCaT cells
a) HaCaT cells were treated with either no treatment or different doses
of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and incubated for
6 hours, b) HaCaT cells were treated with either no treatment or
different doses of UVB (200 J/m2, 400 J/m2, 600 J/m2, 800 J/m2, 1000
J/m2) then cells were incubated for 6 hours. The data represents mean±
SE MVP per ml per 100,000 cells (average of n=3). Groups were
compared using one-way ANOVA. Differences in samples were
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considered significant if the P value were less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***).
It has been found early that aSMase induced MVP release and increased
cytokine release in the MVP23. The inhibition of MVP release and cytokine
from aSMase KO astrocytes indicates that MVP shedding could be
important mediator in release of cytokine from glial cells 23. Hence MVP
shedding via aSMase ceramide pathway is considered important lipid
pathway and studies has shown that it may alter the MVP content via
control release. Though there are several studies related to MVP release
and cytokines in the MVP in other cell lines, very little idea about
keratinocyte derived MVP is known till this date.

We knew the pattern of release of MVP from dose response study of UVB
and CPAF, but as outlined earlier MVP and cytokine content in MVP was
unknown. We investigated cytokine TNF-alpha levels in the supernatant
isolated at same time from the same culture plate for MVP study. The
level of TNF-alpha was measured with high sensitivity Human TNF-alpha
ELISA kit.

To determine the level of TNF-alpha, HaCaT cells were treated with
different doses of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and
UVB (200 J/m2, 400 J/m2, 600 J/m2, 800 J/m2, 1000 J/m2) and culture
plates were incubated for 6 hours. After 6 hours, the supernatant was
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collected and stored at -80ºC. The supernatant was collected at the same
time and from the same plate used to isolate MVP. The concentrations of
MVP and TNF-alpha were determined from the same culture plate. From
Figure 5a, it was seen that concentrations of TNF-alpha increases
significantly with increase in CPAF dose (50nM and 100nM). From Figure

5b, there was a significant increase in the levels of TNF-alpha release
with increased doses of UVB which reached maximum concentration at
400 J/m2 and then slight decreases with higher dose of UVB (600 J/m2,
800 J/m2, 1000 J/m2).
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Figure 5. Dose response effect of CPAF and UVB on TNFalpha production
a) HaCaT cells were treated with either no treatment or different doses
of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and incubated for
6 hours, b) HaCaT cells were treated with either no treatment or
different doses of UVB (200 J/m2, 400 J/m2 ,600 J/m2, 800 J/m2, 1000
J/m2) then cells were incubated for 6 hours. The supernatant was
analyzed for cytokine TNF-alpha by TNF-alpha high sensitivity ELISA
kit. The data represents TNF alpha concentration in pg/ml. Groups were
compared using one-way ANOVA. Differences in samples were
considered significant if the P value were less than P<0.001 (***).

4.2.2 Effect of combination of CPAF and PMA with UVB
on MVP release
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From the dose response studies we sought to combine multiple doses of
CPAF and UVB and determine the potential dose that augments MVP
and cytokine levels. HaCaT cells were treated with multiple stimuli
including different doses of CPAF and UVB. Low dose of CPAF was
combined with high dose of UVB, high dose of UVB with low dose of

CPAF, high dose of both UVB and CPAF, low dose of both UVB and
CPAF and vice-versa. The cells were treated for 6 hours and supernatant
were collected at a time for both MVP and cytokine analysis. From this
study we found that 100nM of CPAF and 600 J/m2 of UVB was sub
optimal dose for potential synergistic effect. From the Figure 6, we
observed approximately 15 folds increase in MVP concentration in
combination of CPAF with UVB and 10 folds increase in MVP release
with combination of PMA and UVB. PMA, Phorbol myristate acetate, a
protein kinase C activator, which is a known positive control that induces
MVP without PAF-R activation.
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Figure 6.Combination of low dose of UVB (600 J/m2) and CPAF
(100nM) induces synergistic increase in MVP release in
HaCaT cells.
HaCaT Cells received no treatment, 0.1% Ethanol, CPAF (100nM), PMA
(500nM), UVB (600 J/m2) or combination of CPAF and PMA with UVB.
Supernatant were collected after 6 hours. MVP level were analyzed using
NanoSight NS300. The data represents mean± SE MVP per ml per
100,000 cells (average of n=3). Groups were compared using one-way
ANOVA. Differences in samples were considered significant if the P value
were less than 0.05. P<0.05 (*), P<0.01(**), and P<0.001 (***).
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4.2.3 Effect of CPAF and PMA with UVB in TNF-alpha
production

We found that combining different stimuli increases MVP release, which
could carry cytokines released after these stimuli. The cytokines are proinflammatory proteins which could cause different inflammatory effects.
To study this first we need to know if combining different stimuli increases
the release of TNF-alpha along with MVP.
The supernatant collected at the same time during MVP isolation were
stored at -80ºC for analysis of cytokine level. The level of TNF-alpha was
analyzed with high sensitivity Human TNF-alpha ELISA kit and
concentration of TNF-alpha was determined with the standard TNF-alpha
provided with the kit. From the figure 7, it is observed there is significant
increase in the level of TNF-alpha in the combination treatment compared
with CPAF/UVB/PMA alone.
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Figure 7. Combination of low dose of UVB (600J/m2) and CPAF
(100nM) induces synergistic increase in TNF-alpha release in
HaCaT cells
HaCaT Cells received no treatment, 0.1% Ethanol as vehicle, CPAF
(100nM), PMA (500nM), UVB (600 J/m2) or combination of CPAF and

PMA with UVB. Supernatants were collected after 6 hours. TNF-alpha
levels were analyzed using High Sensitivity TNF-alpha ELISA kit. Groups
were compared using one-way ANOVA. Differences in samples were
considered significant if the P value were less than P<0.05 (*), P<0.01(**),
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and P<0.001 (***). “#” denotes comparison with CPAF, “&” denotes
comparison with PMA and “^” denotes comparison with UVB.
The high levels of MVP and TNF-alpha in the same supernatant may
indicate inter-connection between MVP and cytokine. Previous studies
from our lab had shown low level of cytokines in MVP compared to control
treatment. It was opposite to what we have hypothesized but the low level
of cytokine in the MVP could be body’s defense mechanism to protect the
body from cytokine storm. In this case combining multiple stimuli, the
exaggerated level of MVP and cytokine in the supernatant could inhibit
the body’s defense mechanism and cytokine could be loaded in the MVP.

The increased level of cytokine in the supernatant could be associated
with the MVP generation. The level of cytokine was measured at 6 hours
after the cells were stimulated with multiple stressors. The study only
shows the level of cytokines in the supernatant from 0-6 hours. These
finding could not be enough to understand about the MVP and its
association with cytokines within short period of time. We do not know
about the peak time when stimulated cells release maximum
concentration of MVP and cytokines and these inflammatory cytokines
could be present in the MVP. The kinetics of release of MVP was studied
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with time response experiments. The level of MVP and cytokine in the
supernatant was measured from 0 to 24 hours.

4.2.4 Time response studies of CPAF/PMA and UVB in
MVP release

The HaCaT cells received no treatment, ethanol (0.1%), CPAF (100nM),
PMA (500nM), UVB (600 J/m2) and combination of CPAF/PMA with UVB.
The supernatants were collected at 0-4 hours, time period, fresh
HBSS+BSA was added to the plates and incubated for another 4 hours.
The sample were collected from 4 to 8 hours and concentration of MVP
and TNF-alpha were analyzed. Similarly, after supernatant was collected
at 8 hours, time point, fresh HBSS+BSA was added to each plate and
incubated for another 16 hours. The supernatants were thus collected
from 0-4 hours, 4-8 hours and 8-24 hours.
From Figure 8, it was observed that there was ~10 folds increase in MVP
release with combination of CPAF with UVB compared to CPAF or UVB
alone. The combination of CPAF/PMA with UVB has also resulted in
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significant increases in the MVP concentrations compared to treatment
alone. The MVP level is significantly higher in the 4-8hour time frame as
compared to 0-4 hour and 8-24 hours. There was no significant
synergistic increase in MVP concentration in between 0-4 hours and 824 hours. These studies suggest that multiple stressors could stimulate

the cells to produce maximum number of MVP in the 4 to 8hour time
frame. This could be the time when body experiences the maximum
amounts of MVP generation along with exaggerated cytokines in the
MVP.
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Figure 8. Time response study of MVP release from
CPAF/PMA/UVB alone and Combination of CPAF/PMA with
UVB.
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HaCaT cells were treated with either no treatment or CPAF/PMA/UVB
and combination of CPAF/PMA with UVB. Supernatant was collected at
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The amount
of MVP released after combination treatment was significantly higher than
control and single treatment particularly at 4-8 hours. The data represents

mean± SE MVP per ml per 100,000 cells (average of n=3). Groups were
compared using two-way ANOVA. Differences in samples were
considered significant if the P value were less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***). ‘#’ denotes comparison with CPAF, ‘&’
denotes comparison with PMA and ‘^’ denotes comparison with UVB.

4.2.4 Time response studies of CPAF/PMA and UVB on
TNF-alpha production

The HaCaT cells received no treatment, vehicle (0.1% ethanol), CPAF
(100nM), PMA (500nM), UVB (600 J/m2) and combination of CPAF and
PMA with UVB. The supernatants were collected at 0 to 4 hours, fresh
HBSS+BSA was added to the plates and incubated for another 4 hours.
The sample were collected from 4 to 8 hours and concentration cytokine
level of was analyzed. Similarly, after supernatant was collected at 8hour
time point, fresh HBSS+BSA was added to each plate and incubated for
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another 16 hours. Thus, the supernatants were collected from 0-4 hours,
4-8 hours and 8-24 hours and TNF-alpha level was measured at these
different time points.
From Figure 9, it was observed that there was a significant increase in
the TNF-alpha level compared to control in both combination treatment
and treatment alone. There were no significant differences in levels of
TNF-alpha at 0 to 4 hours and 4 to 8 hours in both combination and
treatment alone. The time period between 8 to 24 hours has significantly
lower levels of TNF-alpha compared to 0 to 4 hours and 4 to 8hours time
periods.
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Figure 9. Time response study of TNF-alpha release from
CPAF/PMA/UVB alone and Combination of CPAF/PMA with
UVB.
HaCaT cells were treated with either no treatment or CPAF/PMA/UVB
and combination of CPAF/PMA with UVB. Supernatant was collected at
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The
concentration of TNF-alpha after combination treatment was significantly
higher than control and single treatment particularly at 4-8 hours. Groups
were compared using two-way ANOVA. Differences in samples were
considered significant if the P value were less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***). ‘#’ denotes comparison with CPAF, ‘&’
denotes comparison with PMA and ‘^’ denotes comparison with UVB.

4.2.5 Imipramine modulates MVP release in HaCaT cells

Imipramine, an anti-depressant drug, is known to block the release of
MVP via aSMase lipid pathway100. Previous studies have shown the
aSMase inhibitor, imipramine can block MVP release and cytokine (IL1β) in micro glial cells23. Thus, our next studies were designed to test the
ability of imipramine to modulate the release of MVP and cytokine TNFalpha in our system. HaCaT cells were pre-treated with imipramine
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(50µM) for an hour or at the same time with CPAF/PMA/UVB treatment.
From Figure 10, compared to CPAF/UVB/PMA and pre-treatment with
imipramine partially blocked the treatment induced MVP release. It was
also found that UVB induced MVP release is blocked with imipramine. In
UVB, as imipramine blocks UVB and have sunscreen effect, was added

after UVB treatment. Imipramine treatment partially blocks the UVB
induced MVP release.
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Figure 10. Inhibition of MVP release in HaCaT cells in addition
of aSMase inhibitors (Imipramine) for CPAF/PMA/UVB
treatment.
HaCaT cells were pre-treated with Imipramine (50µM) for an hour before
the treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2)
were added and the cells were incubated. Supernatant were collected at
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different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of
MVP was measured with Nano Sight NS300. The data represents mean±
SE MVP per ml per 100,000 cells (average of n=3). Groups were
compared using two-way ANOVA. Differences in samples were
considered significant if the P value were less than 0.05. P<0.05 (*),

P<0.01(**), and P<0.001 (***).
From the above study we determined that the aSMase inhibitor
imipramine partially blocks the release of MVP in treatment alone. As the
combination of different treatments exaggerated the MVP release, we
were curious to learn about the effect of imipramine in inhibition of MVP
release in exaggerated condition. Imipramine has potent sunscreen effect
and blocks the UVB effect, so imipramine was added after the
combination treatment with CPAF and PMA. As shown in Figure 11, it
was found that there were significant differences in MVP release in
combination treatment with imipramine, particularly during the time period
of 4-8 hours. Thus. Imipramine blocks the MVP release in exaggerated
condition with multiple stimuli.
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Figure 11. Inhibition of MVP release in HaCaT cells by addition
of aSMase inhibitors (Imipramine) for combination treatment
(CPAF and UVB).
HaCaT cells were treated with imipramine (50µM) after the combination
treatment. The combination treatment includes CPAF (100nM) and PMA
(500µM) with UVB (600 J/m2) and the cells were incubated. Supernatant
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24
hours. The level of MVP was measured with Nano Sight NS300. The data
represents mean± SE MVP per ml per 100,000 cells (average of n=2).
Groups were compared using two-way ANOVA. Differences in samples
were considered significant if the P value were less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***). # denotes comparison of imipramine
treatment with CPAF and PMA.
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4.2.6 Imipramine modulates TNF-alpha release in HaCaT
cells

Imipramine blocks the MVP release in treatment alone and multiple
treatments. From previous studies we found that MVP release and TNFalpha in the supernatant increases with multiple treatments. Thus, MVP
release from various cells could be an important mechanism by which
cytokine are released. Various studies have shown that imipramine
blocks cytokine release along with MVP shedding. Our next studies were
determined to define the effects of imipramine on TNF-alpha secretion.
HaCaT cells were pre-treated with imipramine (50µM) for an hour or at
the same time with CPAF/PMA/UVB treatment. From Figure 12, it was
known that compared to CPAF/UVB/PMA alone, pre-treatment with

imipramine blunts the effect of treatment induced TNF-alpha release. It
was also found that UVB induced TNF-alpha release was partially
blocked with imipramine. In UVB, as imipramine blocks UVB and have
sunscreen effect, was added after UVB treatment. Imipramine treatment
partially blocks the UVB induced TNF-alpha release.
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Figure 12. Inhibition of TNF-alpha release in HaCaT cells in
addition
of
aSMase
inhibitors
(Imipramine)
for
CPAF/PMA/UVB treatment.
HaCaT cells were pre-treated with imipramine (50µM) for an hour before
the treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2)
were added and the cells were incubated. Supernatant were collected at
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of
TNF-alpha was measured with high sensitivity ELISA kit and data
represents TNF-alpha concentration from three different experiments.
Groups were compared using two-way ANOVA. Differences in samples
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were considered significant if the P value were less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***).

From the above study we determined that imipramine, an aSMase
inhibitor, blocks the release of TNF-alpha in treatment alone. Since
combination of different treatments exaggerated the TNF-alpha release,
we were curious to learn about the effect of imipramine in inhibition of
TNF-alpha release in exaggerated condition. Imipramine has potent
sunscreen effect and blocks the UVB effect, so imipramine was added
after the combination treatment with CPAF and PMA. From Figure 13, we

observed that imipramine blunts the effect of CPAF, and PMA induced
TNF-alpha release in combination with UVB.
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Figure 13. Inhibition of TNF-alpha release in HaCaT cells by
addition of aSMase inhibitor (imipramine) in response to
combination treatment (CPAF/PMA and UVB).
HaCaT cells were treated with imipramine (50µM) after the combination
treatment. The combination treatment includes CPAF (100Nm /PMA
(500nM) with UVB (600 J/m2) and the cells were incubated. Supernatant
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24
hours. The level of TNF-alpha was measured with high sensitivity ELISA
kit and data represents TNF-alpha concentration from three different
experiments. Groups were compared using two-way ANOVA. Differences
in samples were considered significant if the P value were less than 0.05.
P<0.05 (*), P<0.01(**), and P<0.001 (***). # denotes comparison of
imipramine treatment with CPAF and PMA.
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4.3 KBP cells

4.3.1 Dose response effect of CPAF and UVB in MVP
release

Previous studies from our group has found that UVB induces MVP
release in KBP (PAF-R positive cells) yet not in KBM (PAF-R negative
cells). The release of MVP is thus dependent on PAF-Receptor activation.
Cells were stimulated with CPAF, PMA and UVB in normal condition. The
exaggerated condition was not studied before with multiple stimuli. These
studies were to demonstrate the effect of multiple stimulation in KBP cells.

To determine the dose response effect of CPAF and UVB on KBP cells,
various doses of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and
UVB (200 J/m2, 400 J/m2 , 600 J/m2, 800 J/m2, 1000 J/m2) were used to
treat keratinocyte derived KBP cells and incubated at 37ºC for 6 hours.
First, we determined dose response effect of different stimulus and
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figured out potential dose which has maximum effect on MVP release in
PAF-receptor positive cell line KBP. From Figure 14a, it was observed
that 50nM and 100nM of CPAF resulted in increased levels of MVP
release than control while 200nM of CPAF has significant increase in
MVP release compared to control. It was also observed that 250nM of

CPAF induced decreased level of MVP compared to other doses.
Similarly, from Figure 14b using KBP cells, 600 J/m2 has minimum effect
in MVP generation compared with control treatment. While increase in
dose of UVB, (800 J/m2 & 1000 J/m2) there is significant increase in MVP
release compared to control.
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Figure 14. Dose response study of CPAF and UVB in KBP
cells.
a) KBP cells were treated with either no treatment or different doses of
CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and incubated for 6
hours, b) KBP cells were treated with either no treatment or different
doses of UVB (200 J/m2, 400 J/m2, 600 J/m2, 800 J/m2, 1000 J/m2) then
cells were incubated for 6 hours. The data represents mean ± SE MVP
per ml per 100,000 cells (average of n=3). Groups were compared using
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one-way ANOVA. Differences in samples were considered significant if
the P value were less than 0.05. P<0.05 (*), P<0.01(**), and P<0.001
(***). ns denotes no significant.

4.3.2 Dose response effects of CPAF and UVB on TNFalpha generation

The next studies were designed to determine the dose response effect of
CPAF and PMA on TNF-alpha production. To determine the level of TNFalpha, KBP cells were treated with different doses of CPAF (1nM, 10nM,
50nM, 100nM, 200nM, 250nM) and UVB (200 J/m2, 400 J/m2, 600 J/m2,
800 J/m2, 1000 J/m2) and culture plates were incubated for 6 hours. After
6 hours, the supernatant was collected and stored at -80ºC. The
supernatants were collected at the same time and from the same plate
used to isolate MVP. The concentration of MVP level and TNF-alpha was

determined from the same culture plate. From the figure 15a, it was
known that level of TNF-alpha increases significantly with increased
CPAF doses. The high concentration of CPAF decreases the level of
TNF-alpha, indicates MVP release could be potential mediator of release
of cytokines. Similarly, in the UVB irradiated culture plates there is
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significant increases in the levels of TNF-alpha until 400 J/m2 of UVB and
then slight decrease with higher dose of UVB (600 J/m2, 800 J/m2, 1000
J/m2).
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Figure 15. Dose response effect of CPAF and UVB on TNFalpha production.
a) KBP cells were treated with either no treatment or different doses of
CPAF (1nm, 10nm, 50nm, 100nm, 200nm, 250nm) and incubated for 6
hours, b) KBP cells were treated with either no treatment or different
doses of UVB (200 J/m2, 400 J/m2 , 600 J/m2, 800 J/m2, 1000 J/m2) then
cells were incubated for 6 hours. The supernatant was analyzed for
cytokine (TNF-alpha) by TNF-alpha high sensitivity ELISA kit. Data
represents sample from three different experiments. Groups were
compared using one-way ANOVA. Differences in samples were
considered significant if the P value were less than 0.05. P<0.05 (*),

P<0.01(**), and P<0.001 (***).

From our previous studies it was confirmed that MVP release is PAF-R
dependent. The studies were done in PAF-R positive and PAF-R negative
cell lines, KBP and KBM cells. The cells were stimulated with CPAF and

UVB alone. There were no studies conducted testing multiple treatments
to define potential additive/synergistic effects. The KBP and KBM cells,
stimulated with multiple stimuli were tested in the next studies. Both KBP
and KBM were treated with CPAF (100nM), PMA (500nM), UVB (600
J/m2) and combination with CPAF/PMA with UVB. The culture plates
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were incubated for 6 hours. The supernatants were collected and MVP
isolated were analyzed with Nano Sight NS300. It was observed that
there was significant difference in the MVP level in between KBP and
KBM cells in response to CPAF alone and combination of CPAF and UVB
(figure 16). There was no significant difference in PMA treated cells

neither in PMA treatment alone nor in combination treatment. PMA
induces MVP via Protein kinase C pathway.
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Figure 16. MVP release in cells that express PAF-R (KBP) and
cells that do not express PAF-R (KBM).
KBP and KBM cells were treated with no treatment, vehicle (0.1%
ethanol), CPAF (100nM), PMA (500nM), UVB (600 J/m2) and
combination with CPAF/PMA with UVB. The cells were incubated for 6
hours and supernatants were collected for MVP isolation. MVP level were
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measured with Nano Sight NS300. The data represents mean± SE MVP
per ml per 100,000 cells (average of n=3). Groups were compared using
one-way ANOVA. Differences in samples were considered significant if
the P value were less than 0.05. P<0.05 (*), P<0.01(**), and P<0.001
(***).

4.3.3 Time response effects of CPAF and UVB on MVP
release

From the above studies we observed that release of MVP is PAFdependent in both treatments alone and combinations of different stimuli.
We further investigated the time response effects in KBP cells with CPAF
and UVB in order to define the kinetics of MVP in KBP cells. The KBP
cells received no treatment, vehicle (0.1%), CPAF (100nM), PMA
(500nM), UVB (600 J/m2) and combination of CPAF/PMA with UVB. The
supernatants were collected at 0-4 hours, fresh HBSS+BSA was added
to the plates and incubated for another 4 hours. The sample was collected
from 4 to 8 hours and concentration of MVP and cytokine level of was
analyzed. Similarly, after supernatant was collected at 8hours time point,
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fresh HBSS+BSA was added to each plate and incubated for another 16
hours. The supernatants were collected from 0-4 hours, 4-8 hours and 824 hours.
As shown in Figure 19, we observed that there is an increase in particle
release with various treatments compared to control. The combination of
CPAF/PMA with UVB resulted in a significant increase in the MVP
concentration compared to treatment alone. The MVP level is significantly
higher in 4-8hour time compared to 0-4 hour and 8-24 hour. MVP
concentration decreases significantly in 8-24hour time period than other
time period.

There was no significant synergistic increase in MVP

concentration in between 0-4 hours and 8-24 hours. The multiple
stressors could stimulate the cells to produce maximum number of MVP
in 4-8hours time point. This could be the time when body experience
maximum number of MVP generation along with exaggerated cytokines
in the MVP.
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Figure 17. Time response study of CPAF/PMA/UVB alone and
Combination of CPAF/PMA with UVB in KBP cells.
KBP cells were treated with either no treatment or CPAF/PMA/UVB and
combination of CPAF/PMA with UVB. Supernatants were collected at
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The
concentration of TNF-alpha after combination treatment was significantly
higher than control and single treatment particularly at 4-8 hours. The
data represents mean± SE MVP per ml per 100,000 cells (average of
n=3). Groups were compared using two-way ANOVA. Differences in
samples were considered significant if the P value were less than 0.05.
P<0.05 (*), P<0.01(**), and P<0.001 (***). # denotes comparison with
CPAF, “&” denotes comparison with PMA and ^ denotes comparison with
UVB.
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4.3.4 Time response effects of CPAF and UVB on TNFalpha release

The supernatant collected at the same time from the same culture plates
along with MVP isolation were stored at -80ºC. The cytokine TNF-alpha
was measured with high sensitivity human TNF-alpha kit. From the figure
18, it was observed that there was significant increase in the TNF-alpha
level compared to control in both combination treatment and treatment
alone. The level of TNF-alpha is significantly increased in combination
treatment compared to treatment alone. There is no significant difference
in level of TNF-alpha at 0-4 hours and 4-8 hours in both combination and
treatment alone. The time period between 8-24 hours has significantly
lower level of TNF-alpha compared to 0-4 hour and 4-8hour time periods.
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Figure 18. Time response study of CPAF/PMA/UVB alone and
Combination of CPAF/PMA with UVB.
KBP cells were treated with either no treatment or CPAF/PMA/UVB and
combination of CPAF/PMA with UVB. Supernatant was collected at
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The
concentration of TNF-alpha after combination treatment was significantly

higher than control and single treatment particularly at 4-8 hours. Data
represents sample from three different experiments. Groups were
compared using two-way ANOVA. Differences in samples were
considered significant if the P value were less than 0.05. P<0.05 (*),
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P<0.01(**), and P<0.001 (***). # denotes comparison with CPAF, &
denotes comparison with PMA and ^ denotes comparison with UVB.

4.3.5 Imipramine modulates MVP release in KBP cells

Imipramine is an anti-depressant drug known to block MVP release via
inhibition of aSMase enzyme. KBP cells were pre-treated with imipramine
(50µM) for an hour or at the same time with CPAF/PMA/UVB treatment.

Compared to CPAF/UVB/PMA alone, pre-treatment with imipramine
significantly blocked the treatment induced MVP release (Figure 19). It
was also found that UVB induced MVP release is blocked with
Imipramine. In UVB, as imipramine blocks UVB and have sunscreen
effect, was added after UVB treatment.
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Figure 19. Inhibition of MVP release in KBP cells in addition of
aSMase inhibitors (Imipramine) for CPAF/PMA/UVB
treatment.
KBP cells were pre-treated with imipramine (50µm) for an hour before the
treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2) were
added and the cells were incubated. Supernatants were collected at
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of
MVP was measured with Nano Sight NS300. The data represents mean±
SE MVP per ml per 100,000 cells (average of n=3). Groups were
compared using two-way ANOVA. Differences in samples were
considered significant if the P value were less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***).
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From the above study we investigated that imipramine, aSMase inhibitor
blocks the release of MVP in treatment alone. The combination of
different treatments exaggerated the MVP release, we were curious to
learn about the effect of imipramine in inhibition of MVP release in
exaggerated condition. There was significant reduction in MVP release in

combination treatment with imipramine. Imipramine blocks the MVP
release in exaggerated condition with multiple stimuli (Figure 20).
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Figure 20. Inhibition of MVP release in KBP cells in addition of
aSMase inhibitors (Imipramine) for combination treatment
(CPAF/PMA and UVB).
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KBP cells were treated with imipramine (50µM) after the combination
treatment. The combination treatment includes CPAF (100nM), PMA
(500Nm) and UVB (600 J/m2) and the cells were incubated. Supernatant
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24
hours. The level of MVP was measured with Nano Sight NS300. The data

represents mean ± SE MVP per ml per 100,000 cells (average of n=3).
Groups were compared using two-way ANOVA. Differences in samples
were considered significant if the P value were less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***). # represents comparison of imipramine
treatment with CPAF and PMA.

4.3.5 Imipramine modulates TNF-alpha release in KBP
cells

Imipramine blocks the MVP release in treatment alone and in response

to multiple combined treatments. The next studies were designed to
determine the effects of imipramine on TNF-alpha generation in
stimulated conditions. KBP cells were pre-treated with imipramine (50µM)
for an hour or at the same time with CPAF/PMA/UVB treatment. The
supernatants were collected at the same time from the same culture
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plates along with MVP isolation. Compared to CPAF/UVB/PMA alone,
pre-treatment with imipramine blunts the effect of treatment induced TNFalpha release (Figure 21). In UVB, as imipramine blocks UVB and have
sunscreen effect, was added after UVB treatment. From Figure 22, we
observed that imipramine blunts the effect of combination treatment

(CPAF/PMA with UVB) induced TNF-alpha release.
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Figure 21. Inhibition of TNF-alpha release in KBP cells by
addition of aSMase inhibitor (Imipramine) for CPAF/PMA/UVB
treatment.
KBP cells were pre-treated with imipramine (50µM) for an hour before the
treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2) were
added and the cells were incubated. Supernatant were collected at
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of
TNF-alpha was measured with high sensitivity ELISA kit. The data
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represents concentration of TNF-alpha from three different experiment
(average of n=3). Groups were compared using two-way ANOVA.
Differences in samples were considered significant if the P value was less
than 0.05. P<0.05 (*), P<0.01(**), and P<0.001 (***).
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Figure 22. Inhibition of TNF-alpha release in KBP cells by
addition of aSMase inhibitor imipramine for combination
treatments (CPAF/PMA and UVB).
KBP cells were treated with imipramine (50µM) after the combination
treatment. The combination treatment includes CPAF (100nM), PMA
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(500nM) and UVB (600 J/m2) and the cells were incubated. Supernatants
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24
hours. The level of TNF-alpha was measured with TNF-alpha high
sensitivity ELISA kit. The data represents concentration of TNF-alpha
from three different experiment (average of n=3). Groups were compared

using two-way ANOVA. Differences in samples were considered
significant if the P value were less than 0.05. P<0.05 (*), P<0.01(**), and
P<0.001 (***). # denotes comparison of imipramine treatment with CPAF
and PMA.

4.4 Mice

Our next studies were designed to show that in living models the possible
induction of synergistic MVP release in response to the combination of
different stimuli. C57BL/6 wild type mice were used in the studies. The

mice were pre- injected intra-peritoneal with ketamine/xylazine, shaved
and treated with no treatment, vehicle, 100 µl CPAF (100nM), UVB (600
J/m2) and combination of 100µl CPAF (100nM) and UVB (600 J/m2). The
mice were euthanized after 4hours and skin samples were collected by 5
mm punch biopsies. At the same time blood was collected and blood
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plasma was isolated. Skin biopsy was digested in collagenase dispase
overnight and MVP was isolated by centrifugation (2000 x g for 20
minutes in 4ºC and 20,000 x g for 70 minutes in 4 ºC) and MVP
concentration was analyzed by Nano Sight NS300.
The blood plasma was isolated by centrifugation at 2500 x g for 15
minutes and the clear white part of the isolated from the blood was
separated carefully. The separated supernatant was centrifuged at 2000
x g for another 20 minutes to remove cellular debris and blood. MVP was
isolated by centrifugation (2000 x g for 20 minutes in 4 ºC and 20,000 x g
for 70 minutes in 4 ºC) and MVP concentration was analyzed by Nano
Sight NS300. From Figure 23, we observed that there was a significant
increase in particle release with combination treatment compared to
treatment alone and control.
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Figure 23. MVP release in mice skin increases after
combination treatment with CPAF and UVB.
Wild type mice were injected with ketamine xylazine shaved and treated
with no treatment, 100µl of ethanol (100%) as vehicle, 100µl CPAF
(100nM), UVB (1000 J/m²) and the combination. For combination, mice
back were treated with 100µl of 100nM CPAF and after an hour the back
was irradiated with 1000 J/m² of UVB. After 4 hours skin biopsy sample
were collected. MVP concentration was read with Nano Sight NS300. The
data represents mean± SE MVP per ml per gram tissue (average of n=2).

Groups were compared using one-way ANOVA. Differences in samples
were considered significant if the P- value was less than 0.05. P<0.05 (*),
P<0.01(**), and P<0.001 (***). # & ^ represent comparison with CPAF
and UVB respectively.
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Figure 24. MVP release in murine blood increases after
combination treatment with CPAF and UVB.
Wild type mice were injected with ketamine xylazine shaved and treated
with no treatment, 100µl of ethanol (100%) as vehicle, 100µl CPAF
(100nM), UVB (1000 J/m²) and combination. For combination, mice back
were treated with 100µl of 100nM CPAF and after an hour the back was

irradiated with 1000 J/m² of UVB. After 4 hours Blood sample were
collected. MVP concentration was read with Nano Sight NS300. The data
represents mean± SE MVP per ml of blood plasma (average of n=2).
Groups were compared using one-way ANOVA. Differences in samples
were considered significant if the P value was less than 0.05. P<0.05 (*),
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P<0.01(**), and P<0.001 (***). # & ^ represent comparison with CPAF
and UVB respectively.

4.5 MVP Cytokines Levels

Our studies demonstrated that stimulation of HaCaT and KBP cells with
combined stimuli resulted in increased levels of MVP and TNF-alpha in
the supernatants. Thus, multiple stimuli can synergize with each other
and induce the cells to produce high levels of MVP and inflammatory
cytokines. The next studies were designed to test if MVP derived from the
multiple stimuli contained biologically active cytokines. Keratinocytes
derived MVP samples, treated with various stimulus alone/combined
were analyzed by Dr. David Cool for the expression of 27 human
cytokines, chemokines and growth factors listed previously. We were
surprised with the result, as shown in Figure 25, that keratinocyte derived
MVP had more Interlukin-1 receptor antagonist. As mentioned earlier, IL1ra has anti-inflammatory effects which are unique. Skin keratinocytes,
epithelial cells, stromal cells, hepatocytes and adipocytes all secrete ILra39.
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Figure 25. Concentration of IL-1Ra in MVP and supernatant
treated with CPAF/PMA/UVB alone and combination of
CPAF/PMA with UVB.
a) HaCaT cells were treated with CPAF (100nM), PMA (500nM) and UVB
(600 J/m2) and combination of CPAF/PMA with UVB. The supernatants
were collected during 4-8 hours of time period. MVP was isolated from
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the supernatant and stored at -80ºC for analysis of 27 different cytokines,
chemokines and growth factors. b) HaCaT cells were treated with CPAF
(100nM), PMA (500nM) and UVB (600 J/m2) and combination of
CPAF/PMA with UVB. The supernatants were collected during 4-8 hours
of time period. Supernatant was isolated and stored at -80ºC for analysis

of 27 different cytokines, chemokines and growth factors.

Both

supernatant and MVP were analyzed at the same time. Data is
represented pg/MVP count.
There was another surprising finding, along with HaCaT cells, the PAFR-positive epidermoid cell line KBP was treated with same dose of
various treatments, but there was no IL-1ra found in either MVP or
supernatants. This could be due to the reason that only keratinocytes
produce large number of anti-inflammatory cytokines to protect the body.
In one of the previous studies, it was found that there was decreased level
of IL-1Ra in a lupus patient in response to UVB treatment. It was believed
that reduction of IL-1ra in response to UVB was contributing factor to proinflammatory condition, leading to phototoxicity102
From Figure 25, we observed there was increased levels of IL-1ra in
response to UVB treatment in normal keratinocyte derived skin cells,
(HaCaT). This may be a protective effect in normal conditions with less
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sensitizing stimuli, whereas in exaggerated conditions with combination
treatment MVP do not contain IL-1ra. This could be possible mechanism
which exploration could provide further insights about how the defense
mechanism of the body is diminished in exaggerated conditions leading
to local and systemic inflammatory responses.

HaCaT CELLS
MVP
No Treatment
IL-1ra
IL-2
IL-5
IL-8
IL-15
INF-g
MCP 1
Rantes
TNF-alpha
human VEFG

OOR<
OOR<
OOR<
OOR<
OOR<

SUPERNATANT

Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB No Treatment Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB

3.71628866 11.546 3.5486 4.5486 5.5486 6.5486 7.5486 463.335 1213.9 916.09 1159.4 929.2 766.0067 677.2967
0.013149318 0.0111 0.0062 0.0058 0.0129 0.00449 0.0074979
0.205 0.27 0.2833 0.2433 0.84 0.493333 0.406667
0.052095111 0.0411 0.0233 0.0283 0.0294 0.01536 0.0227864
0.97 0.68 0.82 0.9033 1.07 0.813333 0.81
0.009377049 0.1464 3.6393 17.136 0.0973 0.52036 0.2639745 13.645 78.36 54.737 271.76 148.44 129.5367 220.8567
0.456172265 0.3931 0.1475 0.2205 0.2231 0.11201 0.1756152
2.42 4.895 4.5 6.4067 5.1933 3.183333 2.736667
OOR< OOR< OOR< OOR< OOR< OOR<
6.31 15.805 10.903 13.613 6.5633 5.256667 5.51
OOR< OOR< OOR< OOR< OOR< OOR<
12.985 26.22 16.93 14.277 10.91 7.59 6.823333
OOR< OOR< OOR< OOR< OOR< OOR< OOR<
OOR< 13.743 11.1 OOR< OOR< OOR<
OOR< OOR< OOR< OOR< OOR< OOR< OOR<
OOR< OOR< OOR< 66.427 30.80333 27.63
OOR< OOR< OOR< OOR< OOR< OOR< OOR<
OOR< 25.103 70.737 OOR< OOR< OOR<

Table 1. Cytokine, Chemokine and growth factors expressed
in MVP and supernatant isolated from HaCaT cells that
received either no treatment, vehicle, CPAF (100nM), PMA
(500nM), UVB (600 J/m²) and combination of UVB and
CPAF/PMA.
The cytokines not listed here were below the detection threshold both in
MVP and supernatant. INF-g, MCP-1, Rantes, TNF-alpha and human
VEFG were not present in MVP but few treatments contained these
cytokines in supernatant. The data represented are average of three
different samples (n=3). Data is represented in pg/MVP count and pg/ml
for supernatant.
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KBP CELLS
MVP
No Treatment

IL-1ra
IL-2
IL-5
IL-8
IL-15
INF-g
MCP 1
Rantes
TNF-alpha
human VEFG

OOR<

OOR<
OOR<
OOR<
OOR<
OOR<

SUPERNATANT

Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB No Treatment Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB

OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
0.004193548 0.0061 0.005 0.0111 0.0031 0.00414 0.0030777
0.33 0.195 0.8467 1.27 0.2033 0.82 1.476667
0.017593196 0.0278 0.0118 0.0229 0.0184 0.00907 0.0114413
2.37 0.97 1.1433 1 0.7567 0.916667 0.746667
0.009377049 0.1464 3.6393 17.136 0.0973 0.52036 0.2639745
9.5 15.135 262.79 302.51 22.437 24.85 87.28333
0.09650386 0.1501 0.0526 0.1025 0.1305 0.04484 0.0828165 16.69 5.32 3.7733 4.1367 4.4933 3.9 3.806667
OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
OOR< 43.605 59.983 OOR< 40.94 22.855 OOR< OOR< 97.867 151.52 OOR< OOR< OOR<
OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<

Table 2. Cytokine, Chemokine and growth factors expressed
in MVP and supernatant isolated from KBP cells that received
either no treatment, vehicle, CPAF (100nM), PMA (500nM),
UVB (600 J/m²) and combination of UVB and CPAF/PMA.
The cytokines not listed here were below the detection threshold both in
MVP and supernatant. INF-g, MCP-1, Rantes, TNF-alpha and human
VEFG were not present in MVP but few treatments contained these
cytokines in supernatant. The data represented are average of three
different samples (n=3). Data is represented in pg/MVP count and pg/ml
for supernatant.
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Chapter 5: Discussion

5.1 Summary

Ultraviolet B Radiation is a very common environmental stressor which
results in both local and systemic effects. The mechanism involved in a
systemic effect caused by Ultraviolet Radiation is still unknown, though
murine models have demonstrated involvement of PAF. Previous studies
from our lab has already demonstrated that exposure of different
keratinocyte-derived cell lines, murine models and human ex-vivo skin to
ultraviolet B Radiation generates MVP2. The shedding of MVP from
different cell lines like microglial cells, astrocytes, and cancer cell lines
are believed to be involved in cellular responses. It is also thought that
shedding of MVP could be important mechanism in the release of
cytokines. Unfortunately, little is known about MVP generation and proinflammatory cytokines associated with MVP shedding in keratinocytes.
The previous experiments from our lab have shown that treatment of the
keratinocyte-derived cell line HaCaT, with UVB, PAF agonist CPAF and
burn injury resulted in very few cytokines, chemokines and growth factors
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in MVP compared to control treatment. We believe that this might be
protective mechanism body to avoid cytokine storm in the system.
It is unknown how UVB, which is only absorbed by the surface of the skin
exerts systemic effects. The human body has the capacity to defense any
infections, environmental stressors or chemical toxicities in normal
conditions. We hypothesized that in normal stimulated conditions, the
host might may exert defenses to protect against potential cytokine
storms in the system. This might be the reason we observed less
cytokines in the MVP compared to control. But there are some conditions
which these natural defenses could be overridden (for example the case
of Toxic Epidermal Necrolysis reported due to drug sensitivity + tanning
bed treatment1). Along with recreational tanning bed therapy, the
exposure of UV radiation to human skin are sometimes used to self-treat
various skin conditions. The mechanism behind progession of toxic
epidermal necrolysis with tanning bed radiation has not been studied.
Progression of toxic epidermal necrolysis after tanning bed exposure
where different stressors may knowingly or unknowingly combine with
each other to cause exaggerated conditions could be an important clinical
issue and MVP release could be involved in this process. Does the body
exert the same defense mechanism in multiple as well as in normal
stimulated condition? The present studies were designed explore the
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effects of the combination of different stressors on MVP generation and
cytokine release at the same time.
For in vitro studies, human keratinocyte-derived cell line HaCaT and
epidermoid cell line KBP with PAF receptor, were treated with UVB alone,
CPAF alone, PMA alone and combination of UVB with CPAF/PMA. The
samples were collected in different time periods, 0-4 hours/ 4-8 hours/ 824 hours with change in fresh solution each time after the collection of
samples. MVP were isolated and analyzed with Nano Sight NS300. At
the same time samples were analyzed for cytokine (TNF-alpha)
expression. These studies demonstrated synergistic increase in MVP
generation along with TNF-alpha in the supernatant with combination
treatment in human keratinocyte HaCaT and KBP in-vitro.
Further

there

were

several

previously

reported

studies

which

demonstrated that MVP generation is dependent in aSMase pathway 9.
Moreover, cytokines like IL-1β and TNF-alpha in microglial cells and
astrocytes were dependent on the aSMase pathway11,96. We found that
there was synergistic increase in MVP and cytokine release from human
keratinocytes and epidermoid cells. Our next studies were designed to
test if MVP and cytokine generation are interconnected with each other.
Using imipramine, an aSMase inhibitor, we found that imipramine partially
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blocked both MVP and cytokine release in both treatments alone and
combination treatment. Imipramine has potential to block the MVP and
TNF-alpha in exaggerated condition. Since imipramine has potential to
block both MVP and TNF-alpha even in exaggerated condition, this
shows that imipramine could be a potential treatment strategy for blocking

MVP and cytokines like TNF-alpha. It also suggest that MVP could be at
least partially involved in the release of cytokines.
We also investigated whether living models like mice respond to
combination treatments similarly to human keratinocytes and epidermoid
cell line. We treated the backs of wild type mice with no treatment, CPAF
alone, UVB alone and combination with CPAF and UVB. After 4 hours,
skin biopsies and blood sample were harvested, MVP isolated and
analyzed with Nano Sight NS300. As expected, there was synergistic
increase in MVP release in skin sample and blood sample. This supports
our hypothesis that combination of two different stressors, like UVB and
CPAF could result exaggerated MVP generation and exaggerated
release of MVP could be involved in pathological mechanisms of skin
damage resulting in severe systemic complications.
MVP are extra cellular vesicles potentially involved in cellular
communication. They transfer bioactive contents from parent cells of
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origin to different parts of the body leading to various systemic effect in
the body. UVB irradiated human keratinocytes release various cytokines,
PAF agonists, COX-2 and many other bioactive substances. We expect
that the stimulation of cells with combination of different stressors inhibit
the defense mechanism of body and MVP could be loaded with

exaggerated level of cytokines.
Surprisingly, measurement of cytokines contained in MVP did not meet
our hypothesis. We hypothesized that MVP may contain inflammatory
cytokines and transfer the cytokines to other parts of the body leading to
systemic inflammatory responses. The result was opposite to what we
expect, in that MVP expressed low levels of cytokines except for the antiinflammatory cytokines IL-1ra. That irradiation with ultraviolet B Radiation
in normal keratinocytes produced more IL-1ra in both MVP and
supernatant was quite interesting. Previous studies showed that
irradiation of UVB in Polymorphic Light Eruption resulted less in IL-1ra
than in controls101. The decrease in IL-1ra cytokine could contribute in
generation of inflammatory photosensitivity disorders. We believe that
increased levels of IL-1ra in UVB treatment but not in combination of UVB
and CPAF/PMA could have potential importance. In exaggerated
conditions with combination treatment, the release the anti-inflammatory
cytokine IL-1ra could be blocked that could result in imbalance between
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pro- inflammatory cytokines and down regulating responses. This could
ultimately result in pro-inflammatory responses. Previously we reported
that in the patient with toxic epidermal necrolysis associated with tanning
bed use had higher level of TNF-alpha in the skin biopsy and body fluids1,
MVP could have carried higher level of cytokines and resulted in systemic

effect. The result from our studies has shown that there was no TNFalpha in the MVP and increase in IL-1ra in MVP treated with UVB but not
in exaggerated condition with combination treatment. It could be possible
that in UVB irradiation in normal condition has protective effect with
increased level of anti-inflammatory cytokines. But in the case of
combination of UVB with disease or stressed state of cells could block
the protective effect of UVB, leading to a chronic inflammatory state.

5.2 Limitation and Future studies

An important limitation in these studies is that our original multiplex
cytokine analysis has potential flaws as most values were below the limit
of detection. Hence, cytokine analysis could be further investigated.
Another limitation is that the majority of experiments were conducted in
cell lines in vitro. That imipramine did not fully block both MVP and TNF-
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alpha release suggest that the role of MVP in the release of this cytokine
is more complex than originally hypothesized.
The pilot in vivo studies in mice demonstrated increase levels of MVP in
skin biopsy and blood plasma with combination treatment.

Further

studies could be done to measure cytokine expression and inflammatory
responses in murine models, to include using PAF-R and/or aSMase
deficient mice.

5.3 Conclusion

The data from these experiments strongly support that the combination
of different stressors induces synergistic increase in MVP release along
with cytokine TNF-alpha in in-vitro studies. Both MVP and cytokine TNFalpha release seem to be at least partially aSMase enzyme pathway
dependent. Imipramine, aSMase inhibitor blocked MVP and cytokine

significantly,

hence

imipramine

could

potentially

have

clinical

significance. MVP release was time dependent, and these studies show
that the content carried by MVP could be different in a time-dependent
manner and could have different responses. This study shows that MVP
could be involved in pathophysiological mechanisms and cytokines
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carried by these subcellular particles could be involved in pathologies,
especially photosensitivity disorders. The mechanism of cytokine and
MVP and clinical implication of imipramine should be further investigated.
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